Translated from our German original by AI. The German text was researched, written, and edited by the Psychedelia Foundation team and remains the authoritative version.
Systematic analysis of randomized trials finds benefits for PTSD symptoms, dissociation, and level of functioning
MDMA-assisted psychotherapy could reduce the symptom burden of people with post-traumatic stress disorder (PTSD). That is the conclusion of the study Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: A systematic review and meta-analysis of clinical and functional outcomes, which evaluated the randomized controlled trials available on this treatment approach so far.
PTSD is a chronic and often severely disabling mental illness. Against this background, the authors examined whether MDMA-assisted therapy leads to improvements in clinical symptoms and everyday functioning compared with other options.
For the analysis, nine scientific databases and further sources were searched up to 14 August 2025. Of 1,035 publications identified, 14 studies met the criteria for the systematic review. Eight randomized trials provided sufficient data for the quantitative meta-analysis.
The results show a statistically significant advantage of MDMA-assisted therapy for the severity of PTSD symptoms. Based on data from 298 participants, the meta-analysis found a large overall effect in favor of MDMA therapy. The authors also found a significant reduction in dissociative symptoms in 148 participants.
For general everyday functioning, the pooled data from 227 participants likewise showed a statistically significant advantage of MDMA-assisted therapy. For depressive symptoms, by contrast, no clear benefit could be demonstrated.
The authors point out, however, that several methodological problems limit how much the results can carry. The number of available trials remains small, the samples were comparatively small, and the results of individual trials differed considerably in places. Most of the studies also used no active control conditions. Since the subjective effects of MDMA are often noticeable to participants and therapists, this could have compromised blinding and with it the internal validity of the trials.
The quality appraisal found a high risk of bias in outcome measurement in many of the studies. The researchers therefore reach a cautious conclusion: the data so far support further investigation of MDMA-assisted therapy as a potential treatment option for PTSD. To judge its efficacy reliably, however, larger randomized trials with active control groups, improved blinding, and longer follow-up are needed.
